Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

2016-11-17 11:38:21 | BioPortfolio


This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).

Twenty-seven (27) evaluable patients for overall response rate (ORR) will be enrolled in Stage 1. If four or more responses are observed in Stage 1, an additional 15 evaluable patients for ORR will be enrolled in Stage 2. The estimated total enrollment for the trial is 48 patients (assuming a 15% rate of non-evaluable [NE] patients for response).


The trial will consist of the following periods/visits: Screening (Step 1: Confirm ECD-EGFR mutation, Step 2: Full eligibility assessment), Treatment Period, End-of-Treatment Visit, End-of-Trial Visit, and a Safety Follow-up Period.

All patients will receive a loading dose of 9 mg/kg Sym004 maximum 14 days after completed Screening (Step 2) followed by 6 mg/kg weekly (q1w) infusions. Patients will receive mandatory prophylactic treatments for prevention of skin toxicities and infusion related reactions during treatment.

Pre-defined treatment rules apply in case of Sym004 induced skin toxicities and hypomagnesemia. Individual Sym004 dose adjustment in accordance with pre-defined dose modification rules applies in case of Grade 3 anti-EGFR associated skin toxicity and other safety events.

The individual treatment duration is until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from Investigational Medicinal Product (IMP) and/or the trial, or termination of entire trial occurs.

The End-of-Treatment visit will be completed within 10 days after the last dose of IMP and the End-of-Trial Visit will occur no earlier than 28 days after IMP discontinuation.

During the Safety Follow-up period, information on disease progression, subsequent anti-cancer treatment, and survival will be collected every 6 weeks (q6w).

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Metastatic Colorectal Cancer




University of California Los Angeles, Ronald Reagan UCLA Medical Center
Los Angeles
United States


Not yet recruiting


Symphogen A/S

Results (where available)

View Results


Published on BioPortfolio: 2016-11-17T11:38:21-0500

Clinical Trials [4542 Associated Clinical Trials listed on BioPortfolio]

Sym004 Versus TAS-102 in Patients With mCRC

This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-10...

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004 (Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or modotu...

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

The dose-escalation phase of the trial is expected to begin Q4 2015. Patients will be sequentially enrolled to dose-escalation cohorts until establishment of the Maximum Tolerated Dose (MT...

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor...

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

This is a multi-center, open-label, Phase 1b, dose escalation trial of Sym004 administered in combination with 1 of 3 platinum-doublets in subjects with Stage IV Non-Small Cell Lung Cancer...

PubMed Articles [14269 Associated PubMed Articles listed on BioPortfolio]

Antiangiogenic Therapy in Colorectal Cancer.

Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of patients with colorectal cancer will have metastatic disease at the time of initial diagnosis, and approximately 30...

Current status of immunotherapy in metastatic colorectal cancer.

Immunotherapy focuses on selectively enhancing the host's immune response against malignant disease. It has been investigated as an important treatment modality against malignant disease for many year...

First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs.

In light of the relevant expenses of pharmacological interventions, it might be interesting to make a balance between the cost of the new drugs administered and the added value represented by the impr...

Nivolumab for the treatment of colorectal cancer.

Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain sub-optimal. Immunotherapy has been slow to impact the management of th...

Immunodivergence in Metastatic Colorectal Cancer.

Van den Eynde et al. publish in this issue of Cancer Cell that metastatic colorectal cancer shows marked heterogeneity in T cell infiltration among different lesions and patients. Measurements of T...

Medical and Biotech [MESH] Definitions

Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with the formation of colorectal cancer (MCC stands for mutated in colorectal cancer).

Tumor suppressor genes located in the 18q21-qter region of human chromosome 18. The absence of these genes is associated with the formation of colorectal cancer (DCC stands for deleted in colorectal cancer). The products of these genes show significant homology to neural cell adhesion molecules and other related cell surface glycoproteins.

A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.

Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.

More From BioPortfolio on "Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Searches Linking to this Trial